225 related articles for article (PubMed ID: 30418820)
21. Clinical practice. Care of patients receiving long-term anticoagulant therapy.
Schulman S
N Engl J Med; 2003 Aug; 349(7):675-83. PubMed ID: 12917305
[No Abstract] [Full Text] [Related]
22. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
Fanikos J; Burnett AE; Mahan CE; Dobesh PP
Am J Med; 2017 Sep; 130(9):1015-1023. PubMed ID: 28502818
[TBL] [Abstract][Full Text] [Related]
23. Will oral antithrombin agents replace warfarin?
Sinnaeve PR; Van de Werf FJ
Heart; 2004 Aug; 90(8):827-8. PubMed ID: 15253941
[TBL] [Abstract][Full Text] [Related]
24. Dietary implications for patients receiving long-term oral anticoagulation therapy for treatment and prevention of thromboembolic disease.
Kampouraki E; Kamali F
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):789-797. PubMed ID: 28635328
[TBL] [Abstract][Full Text] [Related]
25. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Selçuk H; Selçuk MT; Maden O
Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease.
Noseworthy PA; Yao X; Shah ND; Gersh BJ
Int J Cardiol; 2016 Apr; 209():181-3. PubMed ID: 26896618
[No Abstract] [Full Text] [Related]
27. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
[TBL] [Abstract][Full Text] [Related]
28. Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications.
Barrios V; Escobar C
Expert Rev Cardiovasc Ther; 2013 Feb; 11(2):129-41. PubMed ID: 23405833
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Lenchus JD
Hosp Pract (1995); 2013 Feb; 41(1):49-60. PubMed ID: 23466967
[TBL] [Abstract][Full Text] [Related]
30. The use of oral anticoagulants (warfarin) in older people. AGS Clinical Practices Committee. American Geriatric Society.
J Am Geriatr Soc; 2000 Feb; 48(2):224-7. PubMed ID: 10682955
[No Abstract] [Full Text] [Related]
31. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
Carnicelli AP; De Caterina R; Halperin JL; Renda G; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman E; Giugliano RP;
Circulation; 2017 Mar; 135(13):1273-1275. PubMed ID: 28209729
[No Abstract] [Full Text] [Related]
32. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
[TBL] [Abstract][Full Text] [Related]
33. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
[No Abstract] [Full Text] [Related]
34. The need for new oral anticoagulants in clinical practice.
Hylek EM
J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):605-9. PubMed ID: 19571764
[TBL] [Abstract][Full Text] [Related]
35. Why switch from warfarin to NOACs?
Verdecchia P; Angeli F; Aita A; Bartolini C; Reboldi G
Intern Emerg Med; 2016 Apr; 11(3):289-93. PubMed ID: 26972708
[TBL] [Abstract][Full Text] [Related]
36. Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification.
Cabral KP; Ansell J; Hylek EM
J Thromb Haemost; 2011 Mar; 9(3):441-9. PubMed ID: 21176102
[TBL] [Abstract][Full Text] [Related]
37. Will warfarin ever be replaced?
Ruff CT; Braunwald E
J Cardiovasc Pharmacol Ther; 2010 Sep; 15(3):210-9. PubMed ID: 20484119
[TBL] [Abstract][Full Text] [Related]
38. Novel anticoagulants for stroke prevention in patients with atrial fibrillation.
Jalota A; Scarabelli TM; Saravolatz L; Bakhsh MU; Agrawal P; Jalota R; Chen-Scarabelli C; Fuster V; Halperin J
Cardiovasc Drugs Ther; 2014 Jun; 28(3):247-62. PubMed ID: 24842559
[TBL] [Abstract][Full Text] [Related]
39. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
[TBL] [Abstract][Full Text] [Related]
40. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Bauer KA
Stroke; 2013 Jun; 44(6 Suppl 1):S38-40. PubMed ID: 23709725
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
